PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026npj Vaccines3 citationsOpen Access

The TAK-003 story: key decisions that shaped development of a tetravalent dengue vaccine

View Full Paper
IEIan EscuderoDGDieter GnielSBShibadas Biswal

Key Points

  • The review aims to outline the critical decisions made during the development of the TAK-003 dengue vaccine.
  • Overview of vaccine composition decisions
  • Assessment of safety factors for live-attenuated vaccines
  • Discussion of dosing schedules
  • Immunogenicity assessments
  • Design considerations for the phase 3 efficacy study
  • TAK-003 demonstrates improved safety profiles for live-attenuated vaccines.
  • The vaccine composition supports enhanced immunogenicity against dengue.
  • Phase 3 study reveals critical efficacy metrics for informing vaccination strategies.

Abstract

Abstract The approved, live-attenuated tetravalent dengue vaccine TAK-003 has undergone extensive preclinical and clinical assessment. This review provides an overview of the rationale for some key decisions made during TAK-003 development. These include decisions around vaccine composition, assessment of factors that may be associated with the safety of live-attenuated viral vaccines, dosing schedule, immunogenicity assessments, and design of the pivotal phase 3 efficacy study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Escudero et al. (2026) studied this question.

synapsesocial.com/papers/698433a5f1d9ada3c1fb0effhttps://doi.org/10.1038/s41541-025-01366-9
Ask AI
Helpful
Bookmark
Share
View Full Paper